Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Alzheimer's Disease
Interventions
DRUG

ELND005

DRUG

Placebo

Trial Locations (70)

14620

TransitionTIL Investigational Site, Rochester

14623

TransitionTIL Investigational Site, Rochester

15213

TransitionTIL Investigational Site, Pittsburgh

19001

TransitionTIL Investigational Site, Abington

19046

TransitionTIL Investigational Site, Jenkintown

19104

TransitionTIL Investigational Site, Philadelphia

19107

TransitionTIL Investigational Site, Philadelphia

19401

TransitionTIL Investigational Site, Norristown

20057

TransitionTIL Investigational Site, Washington D.C.

21601

TransitionTIL Investigational Site, Easton

23230

TransitionTIL Investigational Site, Richmond

27103

TransitionTIL Investigational Site, Winston-Salem

27710

TransitionTIL Investigational Site, Durham

28040

TransitionTIL Investigational Site, Madrid

28209

TransitionTIL Investigational Site, Charlotte

28211

TransitionTIL Investigational Site, Charlotte

28401

TransitionTIL Investigational Site, Wilmington

29406

TransitionTIL Investigational Site, North Charleston

29935

TransitionTIL Investigational Site, Port Royal

31419

TransitionTIL Investigational Site, Savannah

31909

TransitionTIL Investigational Site, Columbus

32174

TransitionTIL Investigational Site, Ormond Beach

32806

TransitionTIL Investigational Site, Orlando

33064

TransitionTIL Investigational Site, Deerfield Beach

33137

TransitionTIL Investigational Site, Miami

33334

TransitionTIL Investigational Site, Oakland Park

33351

TransitionTIL Investigational Site, Sunrise

33445

TransitionTIL Investigational Site, Delray Beach

33449

TransitionTIL Investigational Site, Lake Worth

33462

TransitionTIL Investigational Site, Atlantis

33952

TransitionTIL Investigational Site, Port Charlotte

34243

TransitionTIL Investigational Site, Sarasota

35294

TransitionTIL Investigational Site, Birmingham

37212

TransitionTIL Investigational Site, Nashville

39401

TransitionTIL Investigational Site, Hattiesburg

48105

TransitionTIL Investigational Site, Ann Arbor

48993

TransitionTIL Investigational Site, Getxo

49079

TransitionTIL Investigational Site, Paw Paw

55130

TransitionTIL Investigational Site, Saint Paul

62702

TransitionTIL Investigational Site, Springfield

73112

TransitionTIL Investigational Site, Oklahoma City

75115

TransitionTIL Investigational Site, DeSoto

85004

TransitionTIL Investigational Site, Phoenix

85006

TransitionTIL Investigational Site, Phoenix

90073

TransitionTIL Investigational Site, Los Angeles

90720

TransitionTIL Investigational Site, Los Alamitos

90806

TransitionTIL Investigational Site, Long Beach

91316

TransitionTIL Investigational Site, Encino

92025

TransitionTIL Investigational Site, Escondido

92663

TransitionTIL Investigational Site, Newport Beach

92697

TransitionTIL Investigational Site, Irvine

92701

TransitionTIL Investigational Site, Santa Ana

93710

TransitionTIL Investigational Site, Fresno

97225

TransitionTIL Investigational Site, Portland

98007

TransitionTIL Investigational Site, Bellevue

06851

TransitionTIL Investigational Site, Norwalk

04402

TransitionTIL Investigational Site, Bangor

01890

TransitionTIL Investigational Site, Winchester

08084

TransitionTIL Investigational Site, Stratford

T2N-4Z6

TransitionTIL Investigational Site, Calgary

V1Y 3G8

TransitionTIL Investigational Site, Kelowna

M4N 3M5

TransitionTIL Investigational Site, Toronto

M6M 3Z5

TransitionTIL Investigational Site, Toronto

S4T 1A5

TransitionTIL Investigational Site, Regina

03203

TransitionTIL Investigational Site, Elche

08029

TransitionTIL Investigational Site, Barcelona

08221

TransitionTIL Investigational Site, Barcelona

09006

TransitionTIL Investigational Site, Burgos

BA1 3NG

TransitionTIL Investigational Site, Bath

SN3 6BW

TransitionTIL Investigational Site, Swindon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Elan Pharmaceuticals

INDUSTRY

lead

OPKO Health, Inc.

INDUSTRY